2 results for “Actio Biosciences”
Jazz will prioritize ABS-1230 development and integrate Actio’s team while the spinout pursues other rare neurology assets.
The acquisition extends Jazz’s rare-epilepsy franchise beyond Epidiolex and signals continued premium pricing for de-risked rare-disease assets with regulatory designations.
Jazz’s Actio deal will trigger a wave of mid-cap biotech takeouts as buyers chase oncology and neuroscience assets.
An $820 million upfront buy signals continued consolidation as mid-to-large biopharma shops for pipeline depth. The move also underscores investor sensitivity to deal-driven growth narratives, especially when valuation debates are already active.
You're all caught up · last 5 days